CN104432001A - Edible composition and use thereof - Google Patents
Edible composition and use thereof Download PDFInfo
- Publication number
- CN104432001A CN104432001A CN201310430441.0A CN201310430441A CN104432001A CN 104432001 A CN104432001 A CN 104432001A CN 201310430441 A CN201310430441 A CN 201310430441A CN 104432001 A CN104432001 A CN 104432001A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- edible composition
- capsule
- composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- 239000008280 blood Substances 0.000 claims abstract description 36
- 210000004369 blood Anatomy 0.000 claims abstract description 36
- 239000001963 growth medium Substances 0.000 claims abstract description 25
- 230000000968 intestinal effect Effects 0.000 claims abstract description 23
- 230000001105 regulatory effect Effects 0.000 claims abstract description 20
- 235000018291 probiotics Nutrition 0.000 claims abstract description 19
- 239000006041 probiotic Substances 0.000 claims abstract description 18
- 230000000529 probiotic effect Effects 0.000 claims abstract description 16
- 230000036039 immunity Effects 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims description 77
- 239000007788 liquid Substances 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 37
- 230000001580 bacterial effect Effects 0.000 claims description 34
- 241000193171 Clostridium butyricum Species 0.000 claims description 25
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 15
- 241000607142 Salmonella Species 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 13
- 241001531188 [Eubacterium] rectale Species 0.000 claims description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 6
- 241000186394 Eubacterium Species 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 241000605902 Butyrivibrio Species 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 244000199866 Lactobacillus casei Species 0.000 claims description 4
- 241000194036 Lactococcus Species 0.000 claims description 4
- 244000057717 Streptococcus lactis Species 0.000 claims description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 241000193749 Bacillus coagulans Species 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241001464948 Coprococcus Species 0.000 claims description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 241001608234 Faecalibacterium Species 0.000 claims description 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 2
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 claims description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 241000605947 Roseburia Species 0.000 claims description 2
- 241000398180 Roseburia intestinalis Species 0.000 claims description 2
- 241001394655 Roseburia inulinivorans Species 0.000 claims description 2
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 229940054340 bacillus coagulans Drugs 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 abstract description 16
- 229920000377 Sinistrin Polymers 0.000 description 29
- 239000002609 medium Substances 0.000 description 29
- 241000894006 Bacteria Species 0.000 description 25
- 239000000843 powder Substances 0.000 description 23
- 239000000463 material Substances 0.000 description 20
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 108010010803 Gelatin Proteins 0.000 description 18
- 235000013871 bee wax Nutrition 0.000 description 18
- 239000012166 beeswax Substances 0.000 description 18
- 238000001035 drying Methods 0.000 description 18
- 229920000159 gelatin Polymers 0.000 description 18
- 239000008273 gelatin Substances 0.000 description 18
- 235000019322 gelatine Nutrition 0.000 description 18
- 235000011852 gelatine desserts Nutrition 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 235000013406 prebiotics Nutrition 0.000 description 12
- 241000186528 Clostridium tertium Species 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000011888 foil Substances 0.000 description 9
- 239000002054 inoculum Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 238000011218 seed culture Methods 0.000 description 9
- 238000012859 sterile filling Methods 0.000 description 9
- 230000001954 sterilising effect Effects 0.000 description 9
- 238000004659 sterilization and disinfection Methods 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 229940041514 candida albicans extract Drugs 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 229960002433 cysteine Drugs 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013882 gravy Nutrition 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- -1 digestive ferment Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/157—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/161—Mesenteroides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an edible composition, comprising a probiotic culture. The probiotic culture is obtained by cultivating probiotics by using a culture medium. The edible composition disclosed by the invention has the functions of adjusting intestinal flora, regulating blood sugar level, reducing blood fat and improving the immunity.
Description
Technical field
The present invention relates to field of food, specifically, the present invention relates to edible composition and uses thereof.
Background technology
Probio is the active microorganism that a class is useful to host, is colonizated in human body intestinal canal, reproductive system, common are beneficial bacterium and mainly contain clostridium butyricum, lactic acid bacteria, Bifidobacterium etc. in human body.Probio by regulating host's mucous membrane and systemic immune function and improving enteral nutrition and colony balance produces useful physiological action to host, thus plays and improves host intestine flora formation, the digesting and assimilating of promotion nutriment, suppresses the function such as harmful bacteria and harmful substance.
At present, develop hundreds of probiotic products abroad, there are bread and cheese, health products, medicine multiple product type, comprise containing the yoghurt of probio, yogurt, Fermented Soybean Milk and oral liquid, tablet, capsule, powder agent, bacteriostasis spray etc. containing multiple probio.But be that the mode of adjuvant administering drug combinations there is not yet exploitation with probiotic bacterial cultures.
Summary of the invention
The present invention is intended to one of solve the problems of the technologies described above at least to a certain extent.For this reason, one object of the present invention is to propose a kind of edible composition comprising probiotic bacterial cultures, and said composition has regulating intestinal canal flora, hypoglycemic, reducing blood lipid and improves effect of immunity.
The health products of existing prebiotic mushroom or medicine, all with simple thalline for raw material, or add the prebiotics administering drug combinations such as polyfructosan, cottonseed galactooligosaccharide, xylo-oligosaccharide.But be that the mode of adjuvant administering drug combinations there is not yet exploitation with probiotic bacterial cultures.The present inventor finds, culture in probiotic's culture liquid is nutritious, and the metabolite of the probio comprised, vitamin, amino acid, digestive ferment, organic acid, polysaccharide and unidentified growth factor etc. can effectively promote the beneficial bacterium in enteron aisle to breed, and improve animal gastrointestinal tract flora.
For this reason, in one aspect of the invention, the present invention proposes a kind of edible composition.According to a particular embodiment of the invention, said composition comprises probiotic bacterial cultures, and wherein, probiotic bacterial cultures obtains by utilizing culture medium to cultivate probio.This edible composition adds the associated form of its nutrient solution with probio, in adjustment human body intestinal beneficial bacterium group propagation, reduces in blood sugar, reduction blood fat etc., is all significantly better than the combination of independent probio or probio and prebiotics.
Edible composition of the present invention, adopt probio and nutrient solution combination thereof, all raw materials are taken at nature, not containing any chemicals, have no side effect, safe and reliable; And raw material sources are extensively easy to get, prescription compatibility is scientific and reasonable, and determined curative effect has synergistic function, can be effective to regulating intestinal canal flora, reduces blood sugar, reduce blood fat etc.
According to a particular embodiment of the invention, edible composition of the present invention proves without any side effects through the edible test of crowd, there are hypoglycemic, reducing blood lipid significantly, regulating intestinal canal flora, improve the effects such as immunity, meet requirement and the development trend of health products.Serum total cholesterol in the reduction blood of edible composition energy highly significant of the present invention, the content of triglycerides, increase the level of HDL, regulating intestinal canal flora; In adjustment blood sugar, Fasting Glucose can be made significantly to decline.This composition is suitable for hyperglycaemia, high fat of blood, obese people and elderly population etc., is taken by daily, from the angle of effecting a permanent cure, by improving lipid-metabolism, improving blood flow, improving body immunity etc., finally reaches the object protected the health.
In addition, edible composition of the present invention is by the reasonable assembly to pure natural raw material, achieve easily, hypoglycemic, reducing blood lipid significantly, the health-care efficacy such as raising immunity of organisms, drug effect is obvious, security good, steady quality, product can be preserved for a long time, and therefore, this edible composition can be people's daily health caring and provides new selection.
According to one embodiment of present invention, the probio comprised in composition can be the probio of any Pseudomonas, according to a particular embodiment of the invention, this probio can belong to (Faecalibacterium) for being selected from bacillus faecalis of dwelling, Eubacterium (Eubacterium), Luo Sibairui Bordetella (Roseburia), Coprecoccus (Coprococcus), Bifidobacterium (Bifidobacterium), Butyrivibrio (Butyrivibrio), lactobacillus (Bactobacillus), at least one in lactococcus (Lactococcus).This edible composition can be improved thus further and regulating the effect in human body intestinal beneficial bacterium group propagation, reduction blood sugar, reduction blood fat etc.
According to one embodiment of present invention, the concrete probio comprised in composition is also not particularly limited, and according to a particular embodiment of the invention, probio wherein can for being selected from Eubacterium rectale (Eubacterium rectal), food glucose Luo Sibairui Salmonella (Roseburia inulinivorans), enteron aisle Luo Sibairui Salmonella (Roseburia intestinalis), Pu Shi is dwelt bacillus faecalis (Faecalibacterium prausnitzii), clostridium butyricum, bacillus coagulans, bifidobacterium bifidum, bifidobacterium infantis, long Bifidobacterium Bifidum, short Bifidobacterium Bifidum, bifidobacterium adolescentis, Lactobacillus delbrueckii kind, lactobacillus acidophilus, streptococcus thermophilus, L. casei casei, lactobacillus reuteri, bifidobacterium lactis, Lactobacillus casei, Lactobacillus crispatus, lactobacillus delbruockii subspecies bulgaricus, lactobacillus fermenti, lactobacillus gasseri, Lactobacillus helveticus, Yue Shi lactobacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus salivarius, P. freudenreichii ssp subspecies, Lactococcus lactis subsp. lactis, lactococcus lactis subsp, at least one in Lactococcus lactis (biacetyl subspecies) and leuconostoc mesenteroides subsp mesenteroides.This edible composition can be improved thus further and regulating the effect in human body intestinal beneficial bacterium group propagation, reduction blood sugar, reduction blood fat etc.
According to one embodiment of present invention, the type of above-mentioned culture medium is also not particularly limited, according to a particular embodiment of the invention, this culture medium can be solid medium or fluid nutrient medium, the component comprised in culture medium is also not particularly limited, according to a particular embodiment of the invention, carbon source, nitrogenous source, growth factor, inorganic salts and water can be comprised in culture medium.According to a particular embodiment of the invention, carbon source can for being selected from least one in carbohydrate, organic acid, alcohol, lipid, nitrogenous source can for being selected from least one of protein and catabolite in various degree thereof, ammonium salt, nitrate, and growth factor can for being selected from least one of vitamin, amino acid, purine and pyrimidine bases.The life quality of probio can be improved thus further, make to comprise more live probiotics as much as possible in edible composition, improve edible composition so that further and regulating the effect in human body intestinal beneficial bacterium group propagation, reduction blood sugar, reduction blood fat etc.
According to one embodiment of present invention, above-mentioned edible composition can be prepared into any formulation, according to a particular embodiment of the invention, this edible composition can be the form of capsule or oral liquid, can more be convenient to eat thus, to play its effect regulating human body intestinal beneficial bacterium group propagation, reduce blood sugar, reduce the aspects such as blood fat.
In another aspect of this invention, the present invention's proposition can a kind of food.According to a particular embodiment of the invention, this food comprises foregoing edible composition.According to a particular embodiment of the invention, by this food edible in daily life, the effect regulating human body intestinal beneficial bacterium group propagation, reduce blood sugar, reduce the aspects such as blood fat just can be reached.Thus, this food can be functional food or health food.
In another aspect of the invention, the present invention proposes foregoing edible composition and prepare the purposes in preparation, according to a particular embodiment of the invention, said preparation may be used for regulating intestinal canal flora, hypoglycemic, reducing blood lipid and improve immunity one of at least.Owing to containing above-mentioned edible composition in said preparation, because said composition has the quantity increasing probio in enteron aisle, and then there is the effect of regulating intestinal canal flora.Therefore, utilize this edible composition to prepare preparation, effectively can improve said preparation in regulating intestinal canal flora, hypoglycemic, reducing blood lipid and the effect improving the fermentation such as immunity.
In still another aspect of the invention, the present invention proposes foregoing edible composition or the purposes of food in adjustment microbial population of animal intestinal tract.Inventor finds, can be significantly improved the probio quantity in animal intestinal, reach the object of effective regulating intestinal canal colony balance by edible foregoing edible composition or food.The disease such as enteritis, diarrhoea for the treatment of and prevention causes due to intestinal bacilli illness can be effective to thus by this edible composition edible or food.
In another aspect of the invention, the present invention proposes a kind of method of regulating intestinal canal flora, according to a particular embodiment of the invention, the method is for supply foregoing edible composition or food to animal.According to a particular embodiment of the invention, the method can improve the probio quantity be supplied in animal intestinal, effective adjustment microbial population of animal intestinal tract balance, and then the object being reached the blood sugar, blood pressure and the raising immunity that effectively regulate animal by the effect of healthy gut flora.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Detailed description of the invention
Below with reference to specific embodiment, present invention is described, it should be noted that, these embodiments are only descriptive, and do not limit the present invention in any way.
The preparation of embodiment 1 probiotic bacteria culture medium
1. clostridium butyricum, clostridium butyricum culture medium:
Pancreas casein: 5.0g
Peptone (pepsin digestion): 5.0g
Yeast extract: 10.0g
Resazurin: 1.0mg
CaCl
2x2H
2O：0.25g
MgSO
4x7H
2O：0.5g
K
2HPO
4：1.0g
KH
2PO
4：1.0g
NaHCO
3：10.0g
NaCl：2.0g
Cysteine-HCl x H
2O：0.5g
Add ddH
20 is settled to 1L, regulates pH7.0.
2. clostridium tertium culture medium:
Beef extract: 20.0g
Peptone: 30.0g
Yeast extract: 5.0g
K
2HPO
4：5.0g
Resazurin: 1.0mg
Glucose: 4.0g
Cellobiose: 1.0g
Maltose: 1.0g
Soluble starch: 1.0g
Add ddH
2o is settled to 1L, regulates pH7.0.
3. Luo Sibairui Salmonella culture medium
Pancreas casein: 10.0g
Yeast extract: 5.0g
Gravy: 5.0g
Bean powder peptone: 5.0g
Glucose: 5.0g
K
2HPO
4：3.0g
MgSO
4x7H
2O：0.7g
MnSO
4x H
20：0.05g
Tween80：1.0ml
NaCl：7.00g
CaCl
2x2H
2O：0.25g
KH
2PO
4：1.0g
NaHCO
3：10.0g
Cysteine-HCl x H
2O：0.5g
Resazurin (25mg/100ml): 4.0ml
Add ddH
2o is settled to 1L, regulates pH6.8.
4. lactobacillus reuteri culture medium:
Pancreas casein: 10.0g
Gravy: 10.0g
Yeast extract: 5.0g
Glucose: 20.0g
Tween80：1.0g
K
2HPO
4：2.0g
Na-acetate：5.0g
（NH
4）
2citrate：2.0g
Add ddH
2o is settled to 1L, regulates pH6.2-6.5.
5. Miyarisan, Miyarisan culture medium
Cornstarch: 10.0g
Beef peptone: 10.0g
Yeast extract: 5.0g
Sodium acetate: 3.0g
NaCl：5.0g
CaCO
3：3.0g
MgSO
4x7H
2：0.5g
Cysteine-HCl x H
2O：0.5g
Resazurin (25mg/100ml): 4.0ml
Add ddH
2o is settled to 1L, regulates pH7.0.
6. Eubacterium rectale culture medium
Pancreas casein: 5.0g
Peptone: 5.0g
Yeast extract: 10.0g
Beef extract: 5.0g
Glucose: 5.0g
K
2HPO
4：3.0g
Tween80：1.0ml
Cysteine-HCl x H
2O：0.5g
Resazurin: 1.00mg
CaCl
2x2H
2O：0.25g
MgSO
4x7H
2O：0.50g
KH
2PO
4：1.0g
NaHCO
3：10.0g
NaCl：2.00g
Haemin solution：10.0ml
Vitamin K
1solution：0.2ml
Add ddH
2o is settled to 1L, regulates pH7.0.
7. Pu Shi is dwelt bacillus faecalis culture medium
KH
2PO
4：6.0g
NaCl：12.0g
(NH4)
2SO
4：6.0g
CaCl
2x2H
2O：1.6g
MgSO
4x7H
2O：2.5g
K
2HPO
4：0.3g
Pancreas casein: 2.0g
Yeast extract: 0.5g
Volatile fat acid blend: 3.1ml
Hemin: 1.0mg
Glucose: 0.5g
Maltose: 0.5g
Cellobiose: 0.5g
Soluble starch: 0.5g
Glycerine: 0.5g
Na
2CO
3：4.0g
Resazurin: 1.0mg
Cysteine-HCl x H
2O：0.25g
Na
2S x9H
2O：0.25g
Add ddH
2o is settled to 1L, regulates pH6.7-6.8
Volatile fat acid blend:
Acetic acid: 4.25ml
Propionic acid: 1.50ml
Butyric acid: 1.00ml
N-valeric acid: 0.25ml
Isobutyric acid: 0.25ml
DL-2-methylbutanoic acid: 0.25ml
Isovaleric acid: 0.25ml
The preparation of embodiment 2 probio and composition thereof
1. the preparation of clostridium butyricum viable capsule
By clostridium butyricum bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain clostridium butyricum capsule, viable count is not less than 1.0*10
8cFU/g.
2. containing the preparation of the clostridium butyricum viable capsule of polyfructosan
By clostridium butyricum bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of clostridium butyricum, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain clostridium butyricum capsule with No. 0 capsule.
3. the preparation of clostridium butyricum viable bacteria oral liquid
Clostridium butyricum is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the clostridium butyricum fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
4. the preparation of Miyarisan viable capsule
By Miyarisan bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder; Make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain Miyarisan capsule, bacterium number is not less than 1.0*10
8cFU/g.
5. containing the preparation of the Miyarisan viable capsule of polyfructosan
By Miyarisan bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of Miyarisan, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain Miyarisan capsule with No. 0 capsule.
6. the preparation of Miyarisan viable bacteria oral liquid
Miyarisan is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the Miyarisan fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
7. the preparation of Miyarisan viable capsule
By Miyarisan bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain Miyarisan capsule, viable count is not less than 1.0*10
8cFU/g.
8. containing the preparation of the Miyarisan viable capsule of polyfructosan
By Miyarisan bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of Miyarisan, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain Miyarisan capsule with No. 0 capsule.
9. the preparation of Miyarisan viable bacteria oral liquid
Miyarisan is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the Miyarisan fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
10. the preparation of clostridium tertium viable capsule
By clostridium tertium bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain clostridium tertium capsule, viable count is not less than 1.0*10
8cFU/g.
11. containing the preparation of clostridium tertium viable capsule of polyfructosan
By clostridium tertium bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of clostridium tertium, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain clostridium tertium capsule with No. 0 capsule.
The preparation of 12. clostridium tertium viable bacteria oral liquids
Clostridium tertium is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the clostridium tertium fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
The preparation of 13. clostridium butyricum active bacteria capsules
By clostridium butyricum bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain clostridium butyricum capsule, viable count is not less than 1.0*10
8cFU/g.
14. containing the preparation of clostridium butyricum active bacteria capsule of polyfructosan
By clostridium butyricum bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of clostridium butyricum, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain clostridium butyricum capsule with No. 0 capsule.
The preparation of 15. clostridium butyricum active bacteria oral liquids
Clostridium butyricum is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the clostridium butyricum fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
The preparation of 16. lactobacillus reuteri viable capsules
By lactobacillus reuteri bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain lactobacillus reuteri capsule, viable count is not less than 1.0*10
8cFU/g.
17. containing the preparation of lactobacillus reuteri viable capsule of polyfructosan
By lactobacillus reuteri bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of lactobacillus reuteri, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain lactobacillus reuteri capsule with No. 0 capsule.
The preparation of 18. lactobacillus reuteri viable bacteria oral liquids
Lactobacillus reuteri is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the lactobacillus reuteri fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
19. Pu Shi are dwelt the preparation of bacillus faecalis viable capsule
Dwelt by Pu Shi bacillus faecalis bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain Pu Shi and to dwell bacillus faecalis capsule, viable count is not less than 1.0*10
8cFU/g.
20. preparations of to dwell bacillus faecalis viable capsule containing the Pu Shi of polyfructosan
Dwelt by Pu Shi bacillus faecalis bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, the viable count of bacillus faecalis of dwelling according to Pu Shi, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs with No. 0 capsule, obtains Pu Shi and to dwell bacillus faecalis capsule.
21. Pu Shi are dwelt the preparation of bacillus faecalis viable bacteria oral liquid
Bacillus faecalis of being dwelt by Pu Shi access liquid seed culture medium, thermophilic Anaerobic culturel, obtains the sub-liquid of prebiotic bacterial classification.Be that 1-3% access is dwelt in bacillus faecalis fermentation medium through the Pu Shi of sterilization treatment by probio seed liquor according to total inoculum concentration, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
The preparation of 22. Eubacterium rectale viable capsules
By Eubacterium rectale bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, make capsule material with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain Eubacterium rectale capsule, viable count is not less than 1.0*10
8cFU/g.
23. containing the preparation of Eubacterium rectale viable capsule of polyfructosan
By Eubacterium rectale bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of Eubacterium rectale, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs, obtain Eubacterium rectale capsule with No. 0 capsule.
The preparation of 24. Eubacterium rectale viable bacteria oral liquids
Eubacterium rectale is accessed liquid seed culture medium, thermophilic Anaerobic culturel, obtain the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the Eubacterium rectale fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.
The preparation of 25. enteron aisle Luo Sibairui Salmonella viable capsules
By enteron aisle Luo Sibairui Salmonella bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, capsule material is made with gelatin, make end clothing with PVP, then carry out outer dressing with beeswax, pack with No. 0 capsule, obtain enteron aisle Luo Sibairui Salmonella capsule, viable count is not less than 1.0*10
8cFU/g.
26. containing the preparation of enteron aisle Luo Sibairui Salmonella viable capsule of polyfructosan
By enteron aisle Luo Sibairui Salmonella bacterial classification liquid or solid medium culture, collect and washing thalline, drying is prepared into active microbe powder, according to the viable count of enteron aisle Luo Sibairui Salmonella, adds polyfructosan, makes viable count be not less than 1.0*10
8cFU/g, polyfructosan addition is not less than 4g, makes capsule material with gelatin, makes end clothing with PVP, then carries out outer dressing with beeswax, packs with No. 0 capsule, obtains enteron aisle Luo Sibairui Salmonella capsule.
The preparation of 27. enteron aisle Luo Sibairui Salmonella viable bacteria oral liquids
By enteron aisle Luo Sibairui Salmonella access liquid seed culture medium, thermophilic Anaerobic culturel, obtains the sub-liquid of prebiotic bacterial classification.By probio seed liquor according to total inoculum concentration be 1-3% access in the enteron aisle Luo Sibairui Salmonella fermentation medium of sterilization treatment, then plastic foil sealing, leave standstill through filtering after Anaerobic culturel, sterile filling, obtains product, and viable count is not less than 1.0*10
8cFU/ml.Embodiment 3 probio mediator gut flora functional experiment
Regulating intestinal canal flora function human experiment experimental evaluation way according to the Ministry of Public Health " health food inspection and assessment technical specification (2003) " is evaluated.
1. test-meal experiment grouping
Table 1 test-meal experiment grouping sheet
2. human experiment experimental technique
Experimenter is divided at random 27 groups, often organizes 10 people, before experimenter's test-meal, all asepticly take experimenter's ight soil, 16S rDNA checks order inspection gut flora, as the reference of background level.
By the grouping situation of table 1, group 1 takes composition 1, group 2 takes composition 2, group 3 takes composition 3, group 4 takes composition 4, group 5 takes composition 5, group 6 takes composition 6, group 7 takes composition 7, group 8 takes composition 8, group 9 takes composition 9, group 10 takes composition 10, group 11 takes composition 11, group 12 takes composition 12, group 13 takes composition 13, group 14 takes composition 14, group 15 takes composition 15, group 16 takes composition 16, group 17 takes composition 17, group 18 takes composition 18, group 19 takes composition 19, group 20 takes composition 20, group 21 takes composition 21, group 22 takes composition 22, group 23 takes composition 23, group 24 takes composition 24, group 25 takes composition 25, group 26 takes composition 26, group 27 takes composition 27, after 4 weeks, take experimenter's ight soil, 16S rDNA checks order and checks gut flora, contrast with background level, contrast the multiple that its relative abundance increases.
3. gut flora detection method
First fecal sample carries out DNA extraction, V3 ~ V5 region of pcr amplification 16S rDNA, then with 454 platform order-checkings, and order-checking direction V5->V3.Average 7795 tag of each sample initial data, read long about 400bp.The final tag number average out to 3235 for analyzing, reads long about 265bp.
16S analyzes main mothur software (http://www.mothur.org/wiki/Mothur_manual) that adopts and comprises Quality Control, OTU cluster, the analyses such as annotation, and on the basis completing data species taxonomy, analyzes the relative abundance of each species.
4. experimental result
The sequencing data abundance contrast (improving multiple compared with the background level before test-meal) of each Pseudomonas of table 2 people gut flora
Embodiment 4 probiotic composition is hypoglycemic, lipid-lowering test
Auxiliary hyperglycemic, the hypolipemic function human experiment experimental evaluation way of the foundation Ministry of Public Health " health food inspection and assessment technical specification (2003) " are evaluated.
1, probiotic composition preparation:
The single powder of probio (capsule), bacterium powder and polyfructosan (capsule), the bacterium powder composition different with nutrient solution (oral liquid) 3 kinds is prepared according to embodiment 1.
2, human experiment and test method:
Select 270 routine type II diabetes people, the wherein male sex 200 people by the principle of voluntariness, women 70 people, the range of age 43-75 year, without complication such as serious conscience kidneys, contrast design after taking in before test-meal.
Experimenter is divided into 27 groups at random, often organizes 10 people, the former medicine kind of experimenter, diet control and movable constant, by the grouping situation of table 1, group 1 takes composition 1, group 2 takes composition 2, group 3 takes composition 3, group 4 takes composition 4, group 5 takes composition 5, group 6 takes composition 6, group 7 takes composition 7, group 8 takes composition 8, group 9 takes composition 9, group 10 takes composition 10, group 11 takes composition 11, group 12 takes composition 12, group 13 takes composition 13, group 14 takes composition 14, group 15 takes composition 15, group 16 takes composition 16, group 17 takes composition 17, group 18 takes composition 18, group 19 takes composition 19, group 20 takes composition 20, group 21 takes composition 21, group 22 takes composition 22, group 23 takes composition 23, group 24 takes composition 24, group 25 takes composition 25, group 26 takes composition 26, group 27 takes composition 27, daily 1 time, in one after each meal, takes 30 days continuously.
The change of monitoring patient blood pressure, stool and urine, body weight, and the blood sugar (with glucose oxidase method) measuring empty stomach and 2 hours after the meal; Measure blood fat (T-CHOL TC, triglycerides TG and HDL HDL-C).
3, judgment criteria:
Effective: cardinal symptom disappears, on an empty stomach or the blood sugar of 2 hours after the meal comparatively treat before decline and be no more than 30.0%.
Effective: cardinal symptom obviously improves, on an empty stomach and the blood sugar of 2 hours after the meal comparatively treat before decline and be no more than 10.0%.
Invalid: cardinal symptom is not improved, on an empty stomach and the blood sugar of 2 hours after the meal comparatively treat before decline and be less than 10.0%.
4, human experiment result:
Test-meal is after 30 days, take the patient of each group of probiotic composition, compared with before test-meal, the blood pressure of patient, stool and urine, body weight there are no significant difference, but fasting blood-glucose, 2h-plasma glucose all have obvious attenuating, wherein the combination blood sugar decreasing effect of probio and nutrient solution thereof is more remarkable, and concrete outcome is in table 3.
About the patient impact of the blood fat before and after test-meal being taken to each group of probiotic composition, compared with before test-meal, the cholesterol of test-meal patient after 30 days, triglyceride comparatively all have obvious reduction before test-meal, HDL comparatively has obvious rising before test-meal, but the combination blood sugar decreasing effect of probio and nutrient solution thereof is more remarkable, and concrete outcome is in table 4.
As can be seen here, probio of the present invention and nutrient solution combination thereof have the health care of obvious auxiliary hyperglycemic, reducing blood lipid, and to the harmless effect of tested population health.
Table 3 foretastes crowd's blood glucose test results
Table 4 foretastes crowd's lipids detection result
Note: (1) * represents P<0.05; (2) * * represents P<0.01
In the description of this description, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, identical embodiment or example are not necessarily referred to the schematic representation of above-mentioned term.And the specific features of description, structure, material or feature can combine in an appropriate manner in any one or more embodiment or example.
Although illustrate and describe embodiments of the invention above, be understandable that, above-described embodiment is exemplary, can not be interpreted as limitation of the present invention, those of ordinary skill in the art can change above-described embodiment within the scope of the invention when not departing from principle of the present invention and aim, revising, replacing and modification.
Claims (9)
1. an edible composition, is characterized in that, comprises probiotic bacterial cultures, and wherein, described probiotic bacterial cultures obtains by utilizing culture medium to cultivate described probio.
2. edible composition according to claim 1, it is characterized in that, described probio is for being selected from least one of dwelling in bacillus faecalis genus (Faecalibacterium), Eubacterium (Eubacterium), Luo Sibairui Bordetella (Roseburia), Coprecoccus (Coprococcus), Bifidobacterium (Bifidobacterium), Butyrivibrio (Butyrivibrio), lactobacillus (Bactobacillus), lactococcus (Lactococcus).
3. edible composition according to claim 2, is characterized in that, described probio is for being selected from Eubacterium rectale (Eubacterium rectal), food glucose Luo Sibairui Salmonella (Roseburia inulinivorans), enteron aisle Luo Sibairui Salmonella (Roseburia intestinalis), Pu Shi is dwelt bacillus faecalis (Faecalibacterium prausnitzii), clostridium butyricum, bacillus coagulans, bifidobacterium bifidum, bifidobacterium infantis, long Bifidobacterium Bifidum, short Bifidobacterium Bifidum, bifidobacterium adolescentis, Lactobacillus delbrueckii kind, lactobacillus acidophilus, streptococcus thermophilus, L. casei casei, lactobacillus reuteri, bifidobacterium lactis, Lactobacillus casei, Lactobacillus crispatus, lactobacillus delbruockii subspecies bulgaricus, lactobacillus fermenti, lactobacillus gasseri, Lactobacillus helveticus, Yue Shi lactobacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus salivarius, P. freudenreichii ssp subspecies, Lactococcus lactis subsp. lactis, lactococcus lactis subsp, at least one in Lactococcus lactis (biacetyl subspecies) and leuconostoc mesenteroides subsp mesenteroides.
4. edible composition according to claim 1, is characterized in that, described culture medium comprises carbon source, nitrogenous source, growth factor, inorganic salts and water,
Wherein,
Described carbon source is be selected from least one in carbohydrate, organic acid, alcohol, lipid,
Described nitrogenous source is at least one being selected from protein and catabolite in various degree thereof, ammonium salt, nitrate, and
Described growth factor is at least one being selected from vitamin, amino acid, purine and pyrimidine bases.
5. the edible composition according to any one of claim 1-4, is characterized in that, described edible composition is the form of capsule or oral liquid.
6. a food, is characterized in that, comprises the edible composition described in any one of claim 1-5.
7. the edible composition described in any one of claim 1-5 is preparing the purposes in preparation, described preparation be used for regulating intestinal canal flora, hypoglycemic, reducing blood lipid and improve immunity one of at least.
8. the edible composition described in any one of claim 1-5 or food according to claim 6 are regulating the purposes in microbial population of animal intestinal tract.
9. a method for regulating intestinal canal flora, is characterized in that, to the edible composition described in any one of animal supply claim 1-5 or food according to claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310430441.0A CN104432001B (en) | 2013-09-18 | 2013-09-18 | Edible composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310430441.0A CN104432001B (en) | 2013-09-18 | 2013-09-18 | Edible composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104432001A true CN104432001A (en) | 2015-03-25 |
| CN104432001B CN104432001B (en) | 2018-01-12 |
Family
ID=52879348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310430441.0A Active CN104432001B (en) | 2013-09-18 | 2013-09-18 | Edible composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104432001B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105770355A (en) * | 2016-03-17 | 2016-07-20 | 青岛根源生物技术集团有限公司 | Compound preparation for preventing necrotic enteritis of broilers and application of compound preparation |
| CN106562998A (en) * | 2015-10-12 | 2017-04-19 | 深圳华大基因研究院 | Applications of lactobacillus crispatus in treatment or prevention of uterus myoma related diseases |
| CN106666748A (en) * | 2017-01-02 | 2017-05-17 | 郑州国食科技有限公司 | Health food composition with effect of reducing cholesterol |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| WO2018045492A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Faecalibacterium longum and application thereof |
| CN109161494A (en) * | 2018-08-09 | 2019-01-08 | 北京市理化分析测试中心 | With the composite bacteria agent and its preparation method and application for adjusting immune function |
| CN109943510A (en) * | 2019-04-19 | 2019-06-28 | 华南农业大学 | One plant of lactic acid bacillus DU-106 and its application with probiotic properties |
| JP2019137631A (en) * | 2018-02-09 | 2019-08-22 | エースバイオプロダクト株式会社 | Hyperglycemia inhibitor |
| WO2022068273A1 (en) | 2020-09-29 | 2022-04-07 | 青岛蔚蓝生物股份有限公司 | Bacillus coagulans having blood glucose reduction efficacy, and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102210454A (en) * | 2011-04-29 | 2011-10-12 | 张玉国 | Microbial compound preparation and preparation method thereof |
| CN102475725A (en) * | 2010-11-27 | 2012-05-30 | 赵宏伟 | Blood-sugar-reducing and eyesight-improving pill |
-
2013
- 2013-09-18 CN CN201310430441.0A patent/CN104432001B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102475725A (en) * | 2010-11-27 | 2012-05-30 | 赵宏伟 | Blood-sugar-reducing and eyesight-improving pill |
| CN102210454A (en) * | 2011-04-29 | 2011-10-12 | 张玉国 | Microbial compound preparation and preparation method thereof |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106562998A (en) * | 2015-10-12 | 2017-04-19 | 深圳华大基因研究院 | Applications of lactobacillus crispatus in treatment or prevention of uterus myoma related diseases |
| CN105770355A (en) * | 2016-03-17 | 2016-07-20 | 青岛根源生物技术集团有限公司 | Compound preparation for preventing necrotic enteritis of broilers and application of compound preparation |
| CN109874329A (en) * | 2016-08-12 | 2019-06-11 | 深圳华大生命科学研究院 | A kind of production butyric acid is dwelt bacillus faecalis and its cultural method and application |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| US11191790B2 (en) | 2016-08-12 | 2021-12-07 | Bgi Shenzhen | Biologically pure Faecalibacterium butyricigenerans strain, composition including the same and method for treating ulcerative colitis |
| CN109874329B (en) * | 2016-08-12 | 2023-08-29 | 深圳华大生命科学研究院 | Fusarium butyricum and culture method and application thereof |
| WO2018045492A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Faecalibacterium longum and application thereof |
| US10799540B2 (en) | 2016-09-06 | 2020-10-13 | Bgi Shenzhen | Faecalibacterium longum and application thereof |
| CN106666748A (en) * | 2017-01-02 | 2017-05-17 | 郑州国食科技有限公司 | Health food composition with effect of reducing cholesterol |
| JP2019137631A (en) * | 2018-02-09 | 2019-08-22 | エースバイオプロダクト株式会社 | Hyperglycemia inhibitor |
| JP7235270B2 (en) | 2018-02-09 | 2023-03-08 | エースバイオプロダクト株式会社 | Blood sugar elevation inhibitor and method for producing same |
| CN109161494A (en) * | 2018-08-09 | 2019-01-08 | 北京市理化分析测试中心 | With the composite bacteria agent and its preparation method and application for adjusting immune function |
| CN109943510A (en) * | 2019-04-19 | 2019-06-28 | 华南农业大学 | One plant of lactic acid bacillus DU-106 and its application with probiotic properties |
| WO2022068273A1 (en) | 2020-09-29 | 2022-04-07 | 青岛蔚蓝生物股份有限公司 | Bacillus coagulans having blood glucose reduction efficacy, and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104432001B (en) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104432001A (en) | Edible composition and use thereof | |
| Soccol et al. | The potential of probiotics: a review. | |
| Plessas et al. | Potential effects of probiotics in cheese and yogurt production: A review | |
| Timmerman et al. | Monostrain, multistrain and multispecies probiotics—A comparison of functionality and efficacy | |
| CN100469869C (en) | Embedding protection method for beneficial bacteria of intestinal tract | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| CN108783462A (en) | A kind of industrial process of beneficial bacteria of intestinal tract preparation | |
| CN101287478A (en) | Probiotics to influence fat metabolism and obesity | |
| CN105497078A (en) | Novel strain of lactobacillus rhamnosus and metabolites thereof for use in inhibiting xanthine oxidase and treating gout | |
| CN102325464A (en) | Method for alleviating intestinal problems and novel bacterial strains therefor | |
| CN102292431A (en) | Novel lactobacillus plantarum and composition containing the same | |
| CN101171019A (en) | Immune function modulating agents | |
| CN1843385A (en) | Enteral microecological formulation and its preparation process | |
| CN101626774A (en) | Composition for improving intestinal microflora | |
| CN105121627B (en) | Composition containing lactobacillus bacterium | |
| CN110325198A (en) | The purposes in psoriasis is being treated and/or prevented to probiotics | |
| TWI739495B (en) | Composition for promoting defecation and use therefor | |
| Li et al. | Novel vitamin B 12-producing Enterococcus spp. and preliminary in vitro evaluation of probiotic potentials | |
| EP2684469A1 (en) | Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth | |
| CN1273838A (en) | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics | |
| CN103446552B (en) | For the fermentation composition of prevention and therapy digestive system disease | |
| JPWO2018003900A1 (en) | Composition for use in improving nutritional status | |
| Lokhande et al. | A systematic study of probiotics-an update review | |
| JP5254682B2 (en) | Skin property improving agent for oral intake | |
| CN111035661A (en) | Application of lactobacillus plantarum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Edible composition and use thereof Effective date of registration: 20180917 Granted publication date: 20180112 Pledgee: China Minsheng Banking Corp Shenzhen branch Pledgor: BGI SHENZHEN Co.,Ltd. Registration number: 2018440020058 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200410 Granted publication date: 20180112 Pledgee: China Minsheng Banking Corp Shenzhen branch Pledgor: BGI SHENZHEN Co.,Ltd. Registration number: 2018440020058 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230601 Address after: No.7 Pengfei Road, Dapeng Office, Dapeng New Area, Shenzhen City, Guangdong Province, 518000 Patentee after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Patentee before: BGI SHENZHEN Co.,Ltd. |